Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells
Status:
Unknown status
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
In this trial, it will be studied whether early addition of the long acting insulin analogue
Glargine is capable of increasing the number and differentiation of endothelial progenitor
cells (EPC) in patients with type 2 diabetes, which can be seen as a marker of vascular
regenerative potential and cardiovascular risk. In addition, the effect of Glargine on
microvascular function will be studied. This will be done using laser Doppler measurements of
the skin; in addition, MRI of the heart will be performed which is capable of quantifying the
perfusion reserve of the myocardium and additional functional aspects of ventricular
function. A beneficial effect of early addition of bedtime Glargine on EPC and vascular as
well as myocardial function in this study might argue for a change in the therapeutic
approach in type 2 diabetes and possibly improve the cardiovascular outcome in patients
affected.